Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 P211 | DOI: 10.1530/endoabs.81.P211

ECE2022 Poster Presentations Thyroid (136 abstracts)

SARS-CoV-2 Vaccine-Associated Subacute Thyroiditis: Insights from a Systematic Review

Silvia Ippolito 1 , Daniela Gallo 1 , Alessandro Rossini 2 , Bohdan Patera 3 , Nicola Lanzo 3 , Gaia Francesca Maria Fazzino 1,3 , Eliana Piantanida 1,3 & Maria Laura Tanda 1,3


1ASST Sette Laghi, Endocrine Unit, Varese, Italy; 2 ASST Papa Giovanni XXIII, Endocrine Unit, Bergamo, Italy; 3 University of Insubria, Medicine and Surgery, Varese, Italy


Introduction: subacute thyroiditis (SAT) is an inflammatory disease of the thyroid gland causing transient thyrotoxicosis, characterized by neck pain and symptoms of thyroid hormones excess. Viral infections are considered the main trigger of SAT. SAT has also been described after vaccination against H1 N1 vaccine, seasonal influenza virus vaccine, Human Papillomavirus vaccine, and hepatitis B vaccination; more recently, a rising number of cases of SAT following SARS-CoV-2 vaccination has also been reported.

Purpose: perform a systematic review on published cases of subacute thyroiditis secondary to SARS-CoV-2 vaccination, to highlight main features and increase the awareness of this condition.

Methods: original reports of SAT developed after SARS-CoV-2 vaccination (mRNA, viral vector, or inactivated virus vaccines) were retrieved from a search of electronic databases. Individual patient data on demographics, medical history, type of vaccine, workup and therapies were collected. Wilcoxon rank-sum, Kruskal-Wallis and chi-squared tests were employed for comparisons.

Results: 29 articles including 48 reports were retrieved, 3 additional cases evaluated by the Authors were described and included for analysis. Of the 51 patients, 38 (74.5%) were women, median age was 39.5 years (IQR 34-47). Patients developed SAT after a median of 10 days (IQR 4-14) after the vaccine shot. Baseline thyroid exams revealed thyrotoxicosis in 88.2% of patients, decreasing at 31.6% at follow-up. Corticosteroids were used in 56.4% of treated patients. Patients undergoing non-mRNA vaccines were most frequently Asian (P=0.019) and reported more frequently weight loss (P=0.021). All patients with a previous diagnosis of thyroid disease belonged to the mRNA vaccine group.

Conclusions: SARS-CoV-2 vaccine-associated SAT is a novel entity, that should be acknowledged by physicians. Previous history of thyroid disease may predispose to develop SAT after mRNA vaccines, but further studies and larger cohorts are needed to verify this suggestion. SARS-CoV-2 vaccine-associated SAT is usually of mild/moderate severity and could be easily treated in most cases, thus it should not raise any concern regarding the need to be vaccinated.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.